drug
Lialda ER
Marketedupdated 5mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
Trials studying Lialda ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 24, 2027
294 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- May 1, 2030method-of-use (U-1310)US 88656883.6y
- Jun 6, 2028formulationUS 82170831.7y
- Jun 6, 2028formulationUS 84360511.7y
- Jul 24, 2027compositionUS 7645801294d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that